Inactive Instrument

Analyst Reco. Axovant Sciences Ltd Nasdaq

Equities

HC Wainwright Double Downgrades Sio Gene Therapies to Sell From Buy	22-04-28	MT
Cantor Fitzgerald Downgrades Sio Gene Therapies to Neutral From Overweight; Price Target is $0.80	22-04-28	MT
Cantor Adjusts Sio Gene Therapies Price Target to $3 From $8, Maintains Overweight Rating	22-02-01	MT
HC Wainwright Adjusts Price Target on Sio Gene Therapies to $7 From $10, Reiterates Buy Rating	22-02-01	MT
SVB Leerink Downgrades Sio Gene Therapies to Market Perform From Outperform, Adjusts Price Target to $1 From $6	22-02-01	MT
SIO GENE THERAPIES : HC Wainwright Adjusts Sio Gene Therapies PT to $10 From $8, Maintains Buy Rating	21-10-21	MT
SIO GENE THERAPIES : BTIG Starts Sio Gene Therapies at Buy With $8 Price Target	21-06-15	MT
SIO GENE THERAPIES : SVB Leerink Adjusts Sio Gene Therapies' Price Target to $8 From $7, Keeps at Outperform	20-12-16	MT

No results for this search